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Key Points 54 
Question: What are the demographic and clinical characteristics associated with testing 55 
positive for coronavirus 2019 (Covid-19+), and among Covid-19+ subsequent hospitalization 56 
and intensive care among Veterans in the United States?  57 
Findings: In this retrospective cohort study of 2,026,227 Veterans aged 54-75 years and active 58 
in care, 585/3,789 (15.4%) tested Covid-19+. Black race was strongly associated with Covid-19+, 59 
but not with hospitalization or intensive care. Among Covid-19+, laboratory abnormalities and a 60 
summary measure of physiologic injury were strongly associated with hospitalization and 61 
intensive care.  62 
Meaning: Racial differences in testing positive for Covid-19 may be an underestimate of the 63 
general population as racial health disparities in the Veterans Affairs Healthcare System tend to 64 
be smaller than in the private sector. Risk of hospitalization and intensive care may be better 65 
characterized by laboratory measures and vital signs than by comorbid conditions or prior 66 
medication exposure.  67 
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Abstract 68 
Importance: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes 69 
coronavirus disease 2019 (Covid-19), an evolving pandemic. Limited data are available 70 
characterizing SARS-Cov-2 infection in the United States.  71 
Objective: To determine associations between demographic and clinical factors and testing 72 
positive for coronavirus 2019 (Covid-19+), and among Covid-19+ subsequent hospitalization 73 
and intensive care. 74 
Design: Retrospective cohort study including all patients tested for Covid-19 between February 75 
8 and March 30, 2020, inclusive. 76 
Setting: We extracted electronic health record data from the national Veterans Affairs 77 
Healthcare System, the largest integrated healthcare system in the United States. 78 
Participants: Veterans Birth Cohort comprising 2,026,227 patients born between 1945 and 79 
1965 and active in care. 80 
Exposures: Demographic data, comorbidities, medication history, substance use, vital signs, and 81 
laboratory measures. Laboratory tests were analyzed first individually and then grouped into a 82 
validated summary measure of physiologic injury (VACS Index). 83 
Main Outcomes and Measures: We evaluated which factors were associated with Covid-19+ 84 
among all who tested. Among Covid-19+ we identified factors associated with hospitalization or 85 
intensive care. We identified independent associations using multivariable and conditional 86 
multivariable logistic regression with multiple imputation of missing values.  87 
Results: Among Veterans aged 54-75 years, 585/3,789 (15.4%) tested Covid-19+. In adjusted 88 
analysis (C-statistic=0.806) black race was associated with Covid-19+ (OR 4.68, 95% CI 3.79-89 
 5 
5.78) and the association remained in analyses conditional on site (OR 2.56, 95% CI 1.89-3.46). 90 
In adjusted models, laboratory abnormalities (especially fibrosis-4 score [FIB-4] >3.25 OR 8.73, 91 
95% CI 4.11-18.56), and VACS Index (per 5-point increase OR 1.62, 95% CI 1.43-1.84) were 92 
strongly associated with hospitalization. Associations were similar for intensive care. Although 93 
significant in unadjusted analyses, associations with comorbid conditions and medications were 94 
substantially reduced and, in most cases, no longer significant after adjustment. 95 
Conclusions and Relevance: Black race was strongly associated with Covid-19+, but not with 96 
hospitalization or intensive care. Among Covid-19+, risk of hospitalization and intensive care 97 
may be better characterized by laboratory measures and vital signs than by comorbid 98 
conditions or prior medication exposure.   99 
 6 
Introduction 100 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes coronavirus 101 
disease 2019 (Covid-19) and is an evolving pandemic. Limited data are available characterizing 102 
SARS-Cov-2 infection in the United States. Unadjusted analyses restricted to Covid-19 cases in 103 
China,1-5 Italy,6 and the United States7,8 suggest that older age, diabetes, chronic obstructive 104 
lung disease (COPD), hypertension, vascular disease, renal disease, and liver disease are 105 
associated with more severe disease. Further, while some have speculated that use of 106 
angiotensin converting enzyme inhibitor (ACE), angiotensin II receptor blockers (ARB), and 107 
nonsteroidal anti-inflammatory drugs (NSAID) may exacerbate disease,9,10 no analysis of this 108 
question has been published.  109 
 110 
The Department of Veterans Affairs (VA) is the largest integrated healthcare system in the 111 
United States. All care is recorded in a national electronic health record with daily uploads into 112 
a central data repository. As a result, it is possible to extract data on patients tested for Covid-113 
19, including outpatient and inpatient records, laboratory values, and pharmacy fill/refill data. 114 
When a well-characterized longitudinal cohort is supplemented with Covid-19 testing data, it is 115 
possible to answer important questions rapidly using validated methods. 116 
 117 
The VA Birth Cohort includes all Veterans born between 1945 and 1965, over 2 million living 118 
individuals aged 54-75 years,11,12 a demographic at particularly high risk of adverse outcomes 119 
from Covid-19.1-4 Using unadjusted and adjusted analyses, we consider a wide range of factors 120 
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either associated with testing positive for Covid-19 and subsequent hospitalization and 121 
intensive care in the national VA system as of March 30, 2020. 122 
 123 
Methods 124 
Data Source 125 
Using data from the VA national Corporate Data Warehouse on members of the VA Birth 126 
Cohort, we identified patients tested for Covid-19 from date of first recorded VA test on 127 
February 8, 2020 through March 30, 2020. Available data included demographics, outpatient 128 
and inpatient encounters, diagnoses, laboratory results, vital signs, health factors (e.g., smoking 129 
and alcohol health behaviors), and pharmacy dispensing records. 130 
 131 
VA Birth Cohort was approved by the Institutional Review Boards of VA Connecticut Healthcare 132 
System and Yale University. It has been granted a waiver of informed consent and is Health 133 
Insurance Portability and Accountability Act compliant. 134 
 135 
Data Collection 136 
We selected previously validated cohort characteristics and those that have been evaluated in 137 
prior Covid-19 reports.1,13 Baseline was defined as the date of specimen collection for the 138 
Covid-19 test unless testing occurred during hospitalization, in which case it was date of 139 
admission. Demographics included age at baseline, sex, race/ethnicity, and rural/urban 140 
residence. Residence was defined using geographic information system coding based upon 141 
established criteria.14 142 
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 143 
Main Study Outcomes 144 
We examined three outcomes: 1) testing positive for SARS-CoV-2 (Covid-19+), 2) 145 
hospitalization, and 3) admission to an intensive care unit (ICU). We used VA inpatient bed 146 
section codes 12 (medical) and 13 (cardiac) to identify ICU admission.  147 
 148 
Covid-19 tests 149 
We identified Covid-19 tests conducted in the VA using text searching of laboratory results 150 
containing terms consistent with SARS-CoV-2 or Covid-19. If a patient had more than one test 151 
and all were negative we selected first negative, otherwise we used date of first positive. 152 
Patients for whom results were pending (n=93) or inconclusive (n=33) were excluded. Nearly all 153 
tests utilized nasopharyngeal swabs, 1% were from other sources. Testing was performed in VA, 154 
state public health and commercial reference laboratories using emergency use authorization 155 
approved SARS-CoV-2 assays. 156 
 157 
Comorbidity 158 
We extracted diagnostic codes for asthma, cancer, COPD, chronic kidney disease, diabetes 159 
mellitus, hypertension, liver disease, vascular disease, and alcohol use disorder (definitions 160 
provided in eTable 1). We used a validated algorithm to capture smoking status derived from 161 
health factors.15   162 
 163 
Pharmacy Data 164 
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We collected pharmacy fills for ACE/ARBs, chemotherapy and immunosuppressive drugs, and 165 
prescription NSAIDs and determined which medications were active in the year prior to testing. 166 
Exposure windows for NSAIDS ended 14 days prior to baseline to minimize the potential of 167 
protopathic bias. Exposure windows for other medications not used to treat Covid-19 168 
symptoms ended three days prior to baseline.  169 
 170 
Vital Signs, Clinical Laboratory Data, and a Summary Measure of Physiologic Injury 171 
Vital signs measured within two days of baseline included body mass index (BMI), oxygen 172 
saturation, pulse, systolic blood pressure, and temperature. We chose laboratory findings 173 
closest to baseline within a year prior or up to one week after baseline. Measures included 174 
alanine aminotransferase, albumin, aspartate aminotransferase, creatinine, estimated 175 
glomerular filtration rate,16 fibrosis-4 score (FIB-4),17 hemoglobin, platelet count, total white 176 
blood cell count, and lymphocyte count. We calculated a validated composite measure of 177 
physiologic injury (VACS Index) which includes age, BMI, and all previously mentioned  178 
laboratory measures save lymphocyte count18,19 (details in eMethods).  179 
 180 
Statistical Analysis 181 
We evaluated characteristics of patients undergoing Covid-19 testing, and among Covid-19+, 182 
factors associated with hospital admission and intensive care, using chi-square, Fisher’s exact, 183 
and Wilcoxon rank-sum tests, as appropriate. For bivariate comparisons, statistical significance 184 
reflects complete case analysis. When modeling Covid-19+, we restricted analyses to factors 185 
available when initially evaluating a patient (i.e., demographic data, comorbid conditions, 186 
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medication history, health behaviors, and vital signs). Because age, black race, ACE/ARB use, 187 
and NSAID use are of special interest, we included them in all multivariable models. Otherwise, 188 
variables significant at p<0.05 in unadjusted analyses were included in the multivariable 189 
models. When modeling hospital admission and intensive care, we compared C-statistics for 190 
models including individual laboratory values to a model including VACS Index. In post hoc 191 
analyses we explored the association between black race and Covid-19+ with a multivariable 192 
model conditioned on site, among sites having at least five positive tests.  193 
 194 
We report missing data for each variable. We used multiple imputation to impute missing 195 
laboratory measures, vital signs, and smoking status. The imputation model included outcomes 196 
and all covariates. Estimates from regressions performed on 10 imputed data sets were 197 
combined using Rubin's rules.20 Analyses were performed using SAS version 9.4 (SAS Institute 198 
Inc., Cary, NC, USA) and Stata version 14.2 (StataCorp, LLC., College Station, TX). We used R 199 
version 3.6.3 to map Covid-19 cases in the VA system overall and those captured in the VA Birth 200 
Cohort. 201 
 202 
Results 203 
In the year prior to the Covid-19 outbreak, the VA Birth Cohort included 2,026,277 living 204 
individuals: 1,866,256 (92.1%) men and 159,971 (7.9%) women. The cohort includes 1,369,454 205 
(67.6%) white, 402,295 (19.9%) black, 106,639 (5.3%) Latinx, and 147,839 (7.3%) other or 206 
unknown race/ethnicity. More than a third of the subjects (745,284 or 36.8%) were 70-75 years 207 
of age, 23.3% (n=472,732) were 65-69 years old, 20.1% (n=407,900) were 60-64 years old, and 208 
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19.8% (n=400,311) were 54-59 years old. Of these, 3,789 individuals have been tested for 209 
Covid-19 (18.7 per 10,000 persons) since February 8, 2020 through March 30, 2020.  210 
 211 
Testing per 10,000 persons varied by race, sex, age, and residence (p<0.001 for all). Black 212 
Veterans were more likely to be tested than white Veterans (28.0 versus 15.6). Women were 213 
more likely to be tested than men (23.3 versus 18.3). Testing generally decreased with age (age 214 
54-59: 21.5; age 60-64: 22.2; age 65-69: 18.6; and age 70-75: 15.4). Veterans living in urban 215 
settings were more likely to be tested than those in rural settings (39.2 vs. 5.8). 216 
 217 
Among those tested, median age was 65.7 years (Table 1), 90.2% were male, 29.7% were black, 218 
and 81.1% lived in urban settings. Common comorbid conditions were hypertension (65.0%), 219 
diabetes mellitus (37.8%), vascular disease (28.9%), COPD (26.2%), and alcohol use disorder 220 
(13.9%). Receipt of ACE/ARBs (40.5%) or NSAIDs (30.5%) was common. Among those tested, 221 
42.3% were current smokers, 40.8% were obese (BMI >30 kg/m2), 7.7% were febrile (³100.4°F), 222 
13.1% were hypoxic (oxygen saturation £93%), and 35.4% were tachycardic (pulse ³90 beats 223 
per minute).  224 
 225 
Testing Positive vs. Negative for Covid-19 226 
Of the 3,789 patients tested in the VA Birth Cohort, 585 (15.4%, 95% CI 14.3-16.6) were Covid-227 
19+, representing approximately half (585/1244, 47%) of all Covid-19+ patients in the VA as of 228 
March 30, 2020 (Figure 1a and eFigure 1). In unadjusted analyses, factors associated with 229 
Covid-19+ (Table 1) included male sex, black race, urban residence, chronic kidney disease, 230 
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diabetes, and hypertension (all p<0.003). Smoking, COPD, and alcohol use disorder were 231 
associated with a lower probability of a positive test (all p<0.001). No medication exposure was 232 
associated with a positive test. Vital signs associated with Covid-19+ included higher BMI, 233 
tachycardia, and higher temperature (all p<0.001). All laboratory values were associated with 234 
Covid-19+ (all p<0.001). Composite variables, eGFR and FIB-4, were also strongly associated 235 
(both p<0.001).  236 
 237 
In multivariable analyses (Table 2, C-statistic=0.806), black race (OR 4.68,8 95% CI 3.79-5.78), 238 
male sex (OR 3.17, 95% CI 2.03-4.94), urban residence (OR 1.60, 95% CI 1.17-2.20), higher 239 
temperature (OR 1.70, 95% CI 1.58-1.84 per 1°F), lower systolic blood pressure (OR 1.44, 95% CI 240 
1.16-1.78), and prior use of NSAIDS (OR 1.27, 95% CI 1.02-1.58) were associated with increased 241 
likelihood of Covid-19+. Current smoking (OR 0.45, 95% CI 0.35-0.57), alcohol use disorder (OR 242 
0.58, 95% CI 0.41- 0.83), and COPD (OR 0.67, 95%CI 0.50-0.88) were associated with decreased 243 
likelihood of Covid-19+. Results were similar in complete case analysis (eTable 2). 244 
 245 
In post hoc analyses, we observed that black Veterans were more likely to be tested at sites 246 
with higher Covid-19 prevalence (Figure 1b). A model conditional on site (Table 2) reduced the 247 
association with black race (OR 2.56, 95% CI 1.89-3.46) and increased the association with male 248 
sex (OR 3.85, 95% CI 2.20-6.74). Associations with other factors were consistent with 249 
unconditional estimates. 250 
 251 
Risk Factors for Hospitalization and Intensive Care  252 
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Among 585 Covid-19+ patients, 297 (50.8%, 95% CI 46.6-54.9%) were hospitalized and 122 253 
(20.9%, 95% CI 17.6-24.4%) received intensive care. In bivariate analyses, age, chronic kidney 254 
disease, COPD, diabetes, hypertension, vascular disease, ACE/ARB exposure, and decreased 255 
oxygen saturation, and elevated temperature were associated with hospitalization and 256 
intensive care (all p<0.05, Table 3a and Table 3b). All laboratory abnormalities investigated 257 
were associated with hospitalization and intensive care (all p<0.05). Median VACS Index scores 258 
varied substantially between those hospitalized versus not hospitalized (78.7 vs. 66.2, p<0.001) 259 
and between those receiving and not receiving intensive care (82.0 vs. 69.4, p<0.001). 260 
 261 
Parallel models, first adjusted for all significant factors identified in bivariate analyses and then 262 
substituting VACS Index for all laboratory tests, demonstrated good discrimination for 263 
hospitalization (Table 4, C-statistics: 0.859, 0.834) and intensive care (C-statistics: 0.876, 0.835). 264 
White blood cell count, lymphocyte count, eGFR, albumin and FIB-4 were all independently 265 
associated with hospitalization and intensive care (Table 4). The most pronounced association 266 
was for patients with FIB-4>3.25 – adjusted OR 8.73 (95% CI 4.11-18.56) for hospitalization and 267 
8.40 (95% CI 2.90-24.28) for intensive care – compared to those with FIB-4<1.45. Of note, 268 
associations were stronger for FIB-4 and eGFR than for components of these measures (data 269 
not otherwise shown).  270 
 271 
While COPD, diabetes, hypertension, kidney disease, vascular disease and exposure to ACE/ARB 272 
exposure were associated with hospitalization and intensive care in unadjusted analyses, they 273 
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were not significantly associated after adjusting for laboratory abnormalities and vital signs 274 
(Table 4). Results were similar in complete case analysis (eTable 3). 275 
 276 
Discussion 277 
Our analysis represents over 2 million veterans, aged 54-75 years, receiving care in the largest 278 
integrated healthcare system in the United States. The study was conducted within an 279 
established cohort and based on well annotated national electronic health record data, 280 
enabling a rapid and reliable analysis of Covid-19 testing and initial outcomes. As a result, we 281 
were able to validate and extend previous findings, to include a careful consideration of who is 282 
Covid-19+ and, given a positive test, what factors were independently associated with 283 
hospitalization and intensive care. We found that black Veterans were twice as likely to be 284 
tested and 2.5 times as likely to test positive than non-black Veterans, even after adjusting for 285 
urban residence and conditioning on geographic location. While we saw modest evidence of an 286 
association between exposure to NSAIDs and risk of Covid-19+, vital signs and laboratory 287 
measures better characterized risk of hospitalization and intensive care than did comorbid 288 
diagnoses or prior medication exposures.  289 
 290 
In unadjusted analyses, black Veterans were over four times as likely to test positive compared 291 
to non-black Veterans; adjusting for urban versus rural residence did not change this 292 
association. While black Veterans were much more likely to be tested at high prevalence 293 
facilities, conditioning our analysis by site did not eliminate the association; black race retained 294 
over a two-fold increased risk for testing Covid-19+. Of note, black Veterans were also more 295 
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likely to be tested, which could dilute the proportion positive. Further, black Veterans did not 296 
experience higher rates of hospitalization or intensive care. Based on prior experience with 297 
1918 Spanish Flu and 2009 H1N1 epidemic, public health experts have warned that minority 298 
populations may be at higher risk of infection due to reduced capacity to implement physical 299 
distancing.21,22 Our findings may be an underestimate of the US population as racial health 300 
disparities in VA tend to be smaller than in the private sector.23  301 
 302 
Women were more likely to be tested for Covid-19 than men, and men were twice as likely to 303 
test positive. This association strengthened after adjustment and in conditional analyses (Table 304 
2) but should be considered preliminary given limited numbers of women in this analysis.  305 
 306 
As reported previously24 elevated temperature was independently associated with testing 307 
positive, hospital admission and intensive care, underscoring the value of including fever in the 308 
current testing algorithms. Findings from the multivariable regression suggest that other factors 309 
might also be used to indicate a test, including black race, male sex, and lack of an alternative 310 
explanation for cough symptoms. To wit, we found that current smoking, COPD, and alcohol 311 
use disorder, factors that generally increase risk of pneumonia, were associated with decreased 312 
probability of testing positive. While they were not associated with hospitalization or intensive 313 
care, it is too early to tell if these factors are associated with subsequent outcomes such as 314 
respiratory failure or mortality. 315 
 316 
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Presence of particular comorbid diagnoses may be less prognostic than overall acute on chronic 317 
injury reflected in laboratory abnormalities largely encompassed in the VACS Index. In 318 
unadjusted analyses, several comorbid conditions were associated with hospitalization and 319 
intensive care but were not independently associated after adjusting for vital signs and 320 
laboratory data. Further, while elevated white blood cell counts and decreased lymphocyte 321 
counts were associated with hospitalization and intensive care, the pronounced independent 322 
association with FIB-4 (a composite of platelets and transaminases) and albumin suggest that 323 
virally induced hepatic inflammation may be a harbinger of the cytokine storm.25-27  324 
 325 
VACS Index, which includes FIB-4, albumin, and white blood cell count, is predictive of mortality 326 
in many clinical settings.18 A five-point difference in score corresponds to a 30% difference in 327 
mortality. The 12.5-point difference in medians between the Veterans who were and were not 328 
admitted, and the 12.6-point difference between those who received and did not receive 329 
intensive care underscores the wide range of prognoses seen with Covid-19. Future work will 330 
need to determine whether VACS Index might be used in medical triage of Covid-19+ patients.  331 
 332 
Our analysis is one of the first to address concerns regarding exposure to NSAIDS and ACE/ARBs 333 
and Covid-19.9,10 We found NSAID exposure was modestly associated with Covid-19+ in 334 
unadjusted and adjusted analyses, but not with hospitalization or intensive care. Among those 335 
testing positive, ACE/ARB exposure was associated with hospitalization and intensive care in 336 
unadjusted analyses, but associations lost statistical significance with hospitalization and 337 
diminished with intensive care after adjusting for clinical measures, including hypertension and 338 
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blood pressure. However, confidence intervals were wide, include clinically important 339 
differences, and conclusions may change as the epidemic evolves. We will continue to update 340 
these analyses as more data become available. 341 
 342 
While this analysis adds information to the evolving pandemic, its limitations must be kept in 343 
mind. First, a small proportion of Veterans have been tested and rates of testing vary widely by 344 
site. Second, women represented a small number of Veterans in the sample (184 tested, 13 345 
positive). Third, our analysis of outcomes is preliminary as many Covid-19+ patients are still in 346 
care. Fourth, while a strength of this analysis is our ability to determine active VA medications, 347 
we could only detect NSAID exposure based upon VA pharmacy fill/refill data, individuals are 348 
also likely to purchase NSAIDS over the counter. As real-world data become available, more 349 
sophisticated and focused pharmacoepidemiological analyses will be required to address 350 
concerns regarding potential risk of medications associated with Covid-19. 351 
 352 
Conclusion 353 
Black race was strongly associated with Covid-19+, but not with hospitalization or intensive 354 
care. Unadjusted associations between medication exposure, comorbid disease, and 355 
hospitalization and intensive care are diminished after adjustment. Risk of hospitalization and 356 
intensive care associated with Covid-19 may be better characterized by vital signs and 357 
measures of physiologic injury than by comorbid conditions or medication history.   358 
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Figure legends 446 
Figure 1. Distribution of Covid-19 cases in the Veterans Birth Cohort as of March 30, 2020 447 
Caption: (a) Shown is the distribution of 585/1244 (47%) Covid-19 cases in the Veterans Health 448 
Administration captured in the Veterans Birth Cohort as of March 30, 2020 and included in the 449 
current study. (b) Shown is the proportion of Covid-19 test results that are positive by the 450 
proportion of Covid-19 cases of black race by site of care. 451 
  452 
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Table 1. Characteristics of patients tested for Covid-19 among all patients aged 54-75 years in the Veterans Health Administration as of March 30, 2020 
     Covid-19 test result 
  No. tested (%) missing   Positive (%) Negative (%) p-valuea 
% Covid-19+ 
(95% CI) 
Sample size, n 3789 (100.0)   585 (100.0) 3204 (100.0)  15.4 (14.3-16.6)            
Demographics           
Age, years           
  Median (IQR) 65.7 (60.5-70.7) 0  66.1 (60.4-71.0) 65.6 (60.5-70.7) 0.24  
  54-59 861 (22.7)   135 (23.1) 726 (22.7) 0.21 15.7 (13.3-18.3) 
  60-64 906 (23.9)   135 (23.1) 771 (24.1)  14.9 (12.6-17.4) 
  65-69 877 (23.1)   120 (20.5) 757 (23.6)  13.7 (11.5-16.1) 
  70-75 1145 (30.2)   195 (33.3) 950 (29.7)  17.0 (14.9-19.3) 
Sex           
  Female 372 (9.8) 0  27 (4.6) 345 (10.8) <0.001 7.3 (4.8-10.4) 
  Male 3417 (90.2)   558 (95.4) 2859 (89.2)  16.3 (15.1-17.6) 
Race/ethnicity           
  White 2135 (56.3) 0  161 (27.5) 1974 (61.6) <0.001 7.5 (6.5-8.7) 
  Black 1126 (29.7)   350 (59.8) 776 (24.2)  31.1 (28.4-33.9) 
  Latinx 294 (7.8)   48 (8.2) 246 (7.7)  16.3 (12.3-21.1) 
  Other/unknown 234 (6.2)   26 (4.4) 208 (6.5)  11.1 (7.4-15.9) 
Residence type           
  Rural 718 (18.9) 0  56 (9.6) 662 (20.7) <0.001 7.8 (6.0-10.0) 
  Urban 3071 (81.1)   529 (90.4) 2542 (79.3)  17.2 (15.9-18.6)            
Baseline comorbidity           
Asthma           
  No 3506 (92.5) 0  540 (92.3) 2966 (92.6) 0.80 15.4 (14.2-16.6) 
  Yes 283 (7.5)   45 (7.7) 238 (7.4)  15.9 (11.8-20.7) 
Cancer           
  No 3218 (84.9) 0  502 (85.8) 2716 (84.8) 0.57 15.6 (14.4-16.9) 
  Yes 571 (15.1)   83 (14.2) 488 (15.2)  14.5 (11.8-17.7) 
Chronic kidney disease           
  No 3228 (85.2) 0  474 (81.0) 2754 (86.0) 0.003 14.7 (13.5-16.0) 
  Yes 561 (14.8)   111 (19.0) 450 (14.0)  19.8 (16.6-23.3) 
Chronic obstructive pulmonary disease           
  No 2796 (73.8) 0  495 (84.6) 2301 (71.8) <0.001 17.7 (16.3-19.2) 
  Yes 993 (26.2)   90 (15.4) 903 (28.2)  9.1 (7.4-11.0) 
Diabetes mellitus           
  No 2358 (62.2) 0  325 (55.6) 2033 (63.5) <0.001 13.8 (12.4-15.2) 
  Yes 1431 (37.8)   260 (44.4) 1171 (36.5)  18.2 (16.2-20.3) 
Hypertension           
  No 1326 (35.0) 0  162 (27.7) 1164 (36.3) <0.001 12.2 (10.5-14.1) 
  Yes 2463 (65.0)   423 (72.3) 2040 (63.7)  17.2 (15.7-18.7) 
Liver disease           
  No 3323 (87.7) 0  525 (89.7) 2798 (87.3) 0.12 15.8 (14.6-17.1) 
  Yes 466 (12.3)   60 (10.3) 406 (12.7)  12.9 ( 10-16.3) 
Vascular disease           
  No 2694 (71.1) 0  422 (72.1) 2272 (70.9) 0.59 15.7 (14.3-17.1) 
  Yes 1095 (28.9)   163 (27.9) 932 (29.1)  14.9 (12.8-17.1)            
Substance use           
Alcohol use disorder           
  No 3261 (86.1) 0  537 (91.8) 2724 (85.0) <0.001 16.5 (15.2-17.8) 
  Yes 528 (13.9)   48 (8.2) 480 (15.0)  9.1 (6.8-11.9) 
Smoking           
  Never 1042 (27.5) 261  216 (36.9) 826 (25.8) <0.001 20.7 (18.3-23.3) 
  Former 883 (23.3)   179 (30.6) 704 (22.0)  20.3 (17.7-23.1) 
  Current 1603 (42.3)   159 (27.2) 1444 (45.1)  9.9 (8.5-11.5)            
Medication history in year prior to test date           
Any angiotensin converting enzyme inhibitor or 
angiotensin II receptor blocker 
          
  No 2257 (59.6) 0  330 (56.4) 1927 (60.1) 0.10 14.6 (13.2-16.2) 
  Yes 1532 (40.4)   255 (43.6) 1277 (39.9)  16.6 (14.8-18.6) 
  Angiotensin converting enzyme inhibitor           
    No 2778 (73.3) 0  416 (71.1) 2362 (73.7) 0.20 15.0 (13.7-16.4) 
    Yes 1011 (26.7)   169 (28.9) 842 (26.3)  16.7 (14.5-19.2) 
  Angiotensin II receptor blocker           
    No 3226 (85.1) 0  491 (83.9) 2735 (85.4) 0.38 15.2 (14.0-16.5) 
    Yes 563 (14.9)   94 (16.1) 469 (14.6)  16.7 (13.7-20.0) 
Chemotherapy or immunsuppresive drug           
  No 3568 (94.2) 0  556 (95.0) 3012 (94.0) 0.39 15.6 (14.4-16.8) 
  Yes 221 (5.8)   29 (5.0) 192 (6.0)  13.1 (9.0-18.3) 
Nonsteroidal anti-inflammatory drug, (-365, -14 
days) 
          
  No 2634 (69.5) 0  392 (67.0) 2242 (70.0) 0.16 14.9 (13.5-16.3) 
  Yes 1155 (30.5)   193 (33.0) 962 (30.0)  16.7 (14.6-19.0)            
Vital signs at test date            
Body mass index, kg/m2           
  <25.0 779 (20.6) 393  73 (12.5) 706 (22.0) <0.001 9.4 (7.4-11.6) 
  25.0-29.9 1070 (28.2)   166 (28.4) 904 (28.2)  15.5 (13.4-17.8) 
  ≥30 1547 (40.8)   291 (49.7) 1256 (39.2)  18.8 (16.9-20.9) 
Hypoxia (oxygen saturation ≤93%)           
 25 
  No 2433 (64.2) 860  443 (75.7) 1990 (62.1) 0.20 18.2 (16.7-19.8) 
  Yes 496 (13.1)   78 (13.3) 418 (13.0)  15.7 (12.6-19.2) 
Pulse ≥90 beats per minute           
  No 2033 (53.7) 416  295 (50.4) 1738 (54.2) <0.001 14.5 (13.0-16.1) 
  Yes 1340 (35.4)   257 (43.9) 1083 (33.8)  19.2 (17.1-21.4) 
Systolic blood pressure, mm Hg           
    <90 355 (9.4) 448  63 (10.8) 292 (9.1) 0.11 17.8 (13.9-22.1) 
    90-140 1565 (41.3)   274 (46.8) 1291 (40.3)  17.5 (15.7-19.5) 
    ≥140 1421 (37.5)   211 (36.1) 1210 (37.8)  14.9 (13.0-16.8) 
Temperature, °F           
  ≤98.6 2142 (56.5) 405  204 (34.9) 1938 (60.5) <0.001 9.5 (8.3-10.9) 
  98.7-100.3 953 (25.2)   227 (38.8) 726 (22.7)  23.8 (21.2-26.7) 
  ≥100.4 289 (7.6)   120 (20.5) 169 (5.3)  41.5 (35.8-47.4)            
Laboratory findings at test date           
Alanine aminotransferase, U/L           
  Median (IQR) 23.0 (16.0-34.0) 400  28.0 (19.0-41.0) 22.0 (16.0-33.0) <0.001  
  ≤40 2829 (74.7)   406 (69.4) 2423 (75.6) <0.001 14.4 (13.1-15.7) 
  >40 560 (14.8)   138 (23.6) 422 (13.2)  24.6 (21.1-28.4) 
Albumin, g/dL           
  Median (IQR) 3.9 (3.5-4.2) 383  3.8 (3.5-4.2) 3.9 (3.5-4.2) 0.78  
  ≥3.5 2596 (68.5)   415 (70.9) 2181 (68.1) 1.00 16.0 (14.6-17.5) 
  <3.5 810 (21.4)   129 (22.1) 681 (21.3)  15.9 (13.5-18.6) 
Aspartate aminotransferase, U/L           
  Median (IQR) 23.0 (18.0-32.0) 356  29.0 (21.5-43.0) 22.0 (17.0-30.0) <0.001  
  ≤40 2902 (76.6)   391 (66.8) 2511 (78.4) <0.001 13.5 (12.3-14.8) 
  >40 531 (14.0)   157 (26.8) 374 (11.7)  29.6 (25.7-33.7) 
Creatinine, mg/dL           
  Median (IQR) 1.1 (0.9-1.3) 186  1.1 (1.0-1.5) 1.0 (0.9-1.3) <0.001  
  ≤1.5 3033 (80.0)   435 (74.4) 2598 (81.1) <0.001 14.3 (13.1-15.6) 
  >1.5 570 (15.0)   130 (22.2) 440 (13.7)  22.8 (19.4-26.5) 
eGFR, mL/min           
  Median (IQR) 75.0 (59.0-91.0) 168  71.5 (53.0-87.0) 76.0 (60.0-92.0) <0.001  
  ≥15 3492 (92.2)   541 (92.5) 2951 (92.1) 0.11 15.5 (14.3-16.7) 
  <15 129 (3.4)   27 (4.6) 102 (3.2)  20.9 (14.3-29.0) 
FIB-4           
  <1.45 1499 (39.6) 628  139 (23.8) 1360 (42.4) <0.001 9.3 (7.9-10.9) 
  1.45-3.25 1266 (33.4)   263 (45.0) 1003 (31.3)  20.8 (18.6-23.1) 
  >3.25 396 (10.5)   114 (19.5) 282 (8.8)  28.8 (24.4-33.5) 
Hemoglobin, g/dL           
  Median (IQR) 13.8 (12.2-15.0) 445  13.9 (12.6-14.9) 13.8 (12.2-15.0) 0.09  
  ≥10 3097 (81.7)   523 (89.4) 2574 (80.3) <0.001 16.9 (15.6-18.3) 
  <10 247 (6.5)   17 (2.9) 230 (7.2)  6.9 (4.1-10.8) 
Platelet count, K/µL           
  Median (IQR) 218 ( 173- 267) 423  193 ( 154- 230) 223 ( 178- 275) <0.001  
  ≥150 2875 (75.9)   416 (71.1) 2459 (76.7) <0.001 14.5 (13.2-15.8) 
  <150 491 (13.0)   121 (20.7) 370 (11.5)  24.6 (20.9-28.7) 
White blood cell count, K/µL           
  Median (IQR) 7.5 (5.7-10.0) 288  5.9 (4.7-7.5) 7.8 (6.0-10.4) <0.001  
  <4 191 (5.0)   72 (12.3) 119 (3.7) <0.001 37.7 (30.8-45.0) 
  4-9.9 2448 (64.6)   432 (73.8) 2016 (62.9)  17.7 (16.2-19.2) 
  ≥10 862 (22.8)   49 (8.4) 813 (25.4)  5.7 (4.2-7.5) 
  Lymphocyte count, K/µL           
    Median (IQR) 1.4 (1.0-2.0) 628  1.1 (0.8-1.6) 1.5 (1.0-2.1) <0.001  
      ≥0.8 2626 (69.3)   363 (62.1) 2263 (70.6) <0.001 13.8 (12.5-15.2) 
      <0.8 535 (14.1)   130 (22.2) 405 (12.6)  24.3 (20.7-28.2)            
Clinical outcomes           
Hospitalized           
  No  2277 (60.1) 0  288 (49.2) 1989 (62.1) <0.001 12.7 (11.3-14.1) 
  Yes 1512 (39.9)   297 (50.8) 1215 (37.9)  19.6 (17.7-21.7) 
Intensive care unit admission           
  No 3381 (89.2) 0  463 (79.1) 2918 (91.1) <0.001 13.7 (12.6-14.9) 
  Yes 408 (10.8)   122 (20.9) 286 (8.9)  29.9 (25.5-34.6) 
Death during hospitalization           
  No 3744 (98.8) 0  568 (97.1) 3176 (99.1) <0.001 15.2 (14.0-16.4) 
  Yes 45 (1.2)     17 (2.9) 28 (0.9)   37.8 (23.8-53.5) 
Abbreviations: Covid-19, coronavirus disease 2019; IQR, interquartile range; eGFR, estimated glomerular filtration rate, FIB-4, fibrosis 4 score 
aP-values calculated on non-missing data 
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Table 2. Crude and adjusted associations with testing positive for Covid-19 as of March 30, 2020 
 Positive Covid-19 test (n=585/3789) 
  Univariable OR (95% CI) 
Multivariable 
OR (95% CI) 
Conditional    
ORa (95% CI) 
Model details    
C-statistic - 0.806 n/a 
    
Demographics    
Age, per 5-year increase 1.04 (0.97-1.12) 1.05 (0.96-1.15) 1.02 (0.91-1.15) 
Sex, male vs. female 2.49 (1.67-3.73) 3.17 (2.03-4.94) 3.85 (2.20-6.74) 
Race/ethnicity, black vs. other 4.66 (3.88-5.60) 4.68 (3.79-5.78) 2.56 (1.89-3.46) 
Residence type, urban vs. rural 2.46 (1.84-3.28) 1.60 (1.17-2.20) 1.04 (0.64-1.68) 
    
Baseline comorbidity    
Chronic kidney disease, yes vs. no 1.43 (1.14-1.80) 1.00 (0.76-1.33) 0.92 (0.64-1.31) 
Chronic obstructive pulmonary disease, yes vs. no 0.46 (0.37-0.59) 0.67 (0.50-0.88) 0.77 (0.54-1.09) 
Diabetes mellitus, yes vs. no  1.39 (1.16-1.66) 1.01 (0.80-1.26) 0.89 (0.67-1.19) 
Hypertension, yes vs.no  1.49 (1.23-1.81) 1.23 (0.95-1.60) 1.40 (1.00-1.96) 
    
Substance use    
Alcohol use disorder, yes vs. no 0.51 (0.37-0.69) 0.58 (0.41-0.83) 0.52 (0.34-0.82) 
Current smoking, yes vs. no 0.43 (0.35-0.52) 0.45 (0.35-0.57) 0.45 (0.34-0.61) 
    
Medication history in year prior to test date    
Angiotensin converting enzyme inhibitor or 
angiotensin II receptor blocker, yes vs. no 1.17 (0.98-1.39) 0.98 (0.78-1.23) 0.93 (0.69-1.24) 
Nonsteroidal anti-inflammatory drug, yes vs. no 1.15 (0.95-1.39) 1.27 (1.02-1.58) 1.16 (0.87-1.54) 
    
Vital signs    
Systolic blood pressure, <140 vs. ≥140 mm Hg 1.25 (1.03-1.51) 1.44 (1.16-1.78) 1.29 (0.99-1.69) 
Body mass index, per 5 kg/m2 increase 1.15 (1.08-1.23) 1.09 (1.00-1.18) 1.10 (0.99-1.22) 
Oxygen saturation, ≤93% vs >93% 0.88 (0.68-1.15) 1.04 (0.76-1.42) 1.04 (0.67-1.61) 
Pulse, per 5-beats per minute increase 0.99 (0.99-1.00) 0.99 (0.99-1.00) 1.00 (0.99-1.00) 
Temperature, per 1°F increase 1.74 (1.62-1.87) 1.70 (1.58-1.84) 1.69 (1.53-1.88) 
Abbreviations: Covid-19, coronavirus disease 2019; OR, odds ratio; CI, confidence interval 
aModeling stations with five or more Covid-19 cases and conditioning on station 
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Table 3a. Associations with hospitalization among Covid-19 cases aged 54-75 years in the Veterans Health Administration as of March 30, 2020 
     Hospitalization 
  No. cases (%) missing   Yes (%) No (%) p-valuea 
% hospitalized 
(95% CI) 
n 585 (100)   297 (100.0) 288 (100.0)  50.8 (46.6-54.9)            
Demographics           
Age, years           
  Median (IQR) 66.1 (60.4-71.0) 0  67.6 (61.7-71.6) 64.5 (59.7-70.5) 0.001  
  54-59 135 (23.1)   58 (19.5) 77 (26.7) 0.02 43.0 (34.5-51.8) 
  60-64 135 (23.1)   62 (20.9) 73 (25.3)  45.9 (37.3-54.7) 
  65-69 120 (20.5)   62 (20.9) 58 (20.1)  51.7 (42.4-60.9) 
  70-75 195 (33.3)   115 (38.7) 80 (27.8)  59.0 (51.7-66.0) 
Sex           
  Female 27 (4.6) 0  8 (2.7) 19 (6.6) 0.03 29.6 (13.8-50.2) 
  Male 558 (95.4)   289 (97.3) 269 (93.4)  51.8 (47.6-56.0) 
Race/ethnicity           
  White 161 (27.5) 0  79 (26.6) 82 (28.5) 0.32 49.1 (41.1-57.1) 
  Black 350 (59.8)   187 (63.0) 163 (56.6)  53.4 (48.1-58.8) 
  Latinx 48 (8.2)   20 (6.7) 28 (9.7)  41.7 (27.6-56.8) 
  Other/unknown 26 (4.4)   11 (3.7) 15 (5.2)  42.3 (23.4-63.1) 
Residence type           
  Rural 56 (9.6) 0  27 (9.1) 29 (10.1) 0.78 48.2 (34.7-62.0) 
  Urban 529 (90.4)   270 (90.9) 259 (89.9)  51.0 (46.7-55.4)            
Baseline comorbidity           
Asthma           
  No 540 (92.3) 0  273 (91.9) 267 (92.7) 0.76 50.6 (46.3-54.9) 
  Yes 45 (7.7)   24 (8.1) 21 (7.3)  53.3 (37.9-68.3) 
Cancer           
  No 502 (85.8) 0  252 (84.8) 250 (86.8) 0.55 50.2 (45.7-54.7) 
  Yes 83 (14.2)   45 (15.2) 38 (13.2)  54.2 (42.9-65.2) 
Chronic kidney disease           
  No 474 (81.0) 0  222 (74.7) 252 (87.5) <0.001 46.8 (42.3-51.4) 
  Yes 111 (19.0)   75 (25.3) 36 (12.5)  67.6 (58.0-76.2) 
Chronic obstructive pulmonary disease           
  No 495 (84.6) 0  236 (79.5) 259 (89.9) <0.001 47.7 (43.2-52.2) 
  Yes 90 (15.4)   61 (20.5) 29 (10.1)  67.8 (57.1-77.3) 
Diabetes mellitus           
  No 325 (55.6) 0  141 (47.5) 184 (63.9) <0.001 43.4 (37.9-49.0) 
  Yes 260 (44.4)   156 (52.5) 104 (36.1)  60.0 (53.8-66.0) 
Hypertension           
  No 162 (27.7) 0  59 (19.9) 103 (35.8) <0.001 36.4 (29.0-44.3) 
  Yes 423 (72.3)   238 (80.1) 185 (64.2)  56.3 (51.4-61.1) 
Liver disease           
  No 525 (89.7) 0  260 (87.5) 265 (92.0) 0.08 49.5 (45.2-53.9) 
  Yes 60 (10.3)   37 (12.5) 23 (8.0)  61.7 (48.2-73.9) 
Vascular disease           
  No 422 (72.1) 0  184 (62.0) 238 (82.6) <0.001 43.6 (38.8-48.5) 
  Yes 163 (27.9)   113 (38.0) 50 (17.4)  69.3 (61.6-76.3)            
Substance use           
Alcohol use disorder           
  No 537 (91.8) 0  269 (90.6) 268 (93.1) 0.29 50.1 (45.8-54.4) 
  Yes 48 (8.2)   28 (9.4) 20 (6.9)  58.3 (43.2-72.4) 
Smoking           
  Never 216 (36.9) 31  106 (35.7) 110 (38.2) 0.30 49.1 (42.2-55.9) 
  Former 179 (30.6)   89 (30.0) 90 (31.3)  49.7 (42.2-57.3) 
  Current 159 (27.2)   90 (30.3) 69 (24.0)  56.6 (48.5-64.4)            
Medication history in year prior to test date           
Any angiotensin converting enzyme inhibitor or 
angiotensin II receptor blocker 
          
  No 330 (56.4) 0  150 (50.5) 180 (62.5) 0.004 45.5 (40.0-51.0) 
  Yes 255 (43.6)   147 (49.5) 108 (37.5)  57.7 (51.3-63.8) 
Angiotensin converting enzyme inhibitor           
    No 416 (71.1) 0  194 (65.3) 222 (77.1) 0.002 46.6 (41.8-51.6) 
    Yes 169 (28.9)   103 (34.7) 66 (22.9)  61.0 (53.2-68.4) 
Angiotensin II receptor blocker           
    No 491 (83.9) 0  248 (83.5) 243 (84.4) 0.82 50.5 (46.0-55.0) 
    Yes 94 (16.1)   49 (16.5) 45 (15.6)  52.1 (41.6-62.5) 
Chemotherapy or immunsuppresive drug           
  No 556 (95.0) 0  279 (93.9) 277 (96.2) 0.25 50.2 (45.9-54.4) 
  Yes 29 (5.0)   18 (6.1) 11 (3.8)  62.1 (42.3-79.3) 
Nonsteroidal anti-inflammatory drug, (-365, -14 days)           
    No 392 (67.0) 0  207 (69.7) 185 (64.2) 0.19 52.8 (47.7-57.8) 
    Yes 193 (33.0)   90 (30.3) 103 (35.8)  46.6 (39.4-53.9)            
Vital signs at test date            
Body mass index, kg/m2           
  <25.0 73 (12.5) 55  45 (15.2) 28 (9.7) 0.25 61.6 (49.5-72.8) 
  25.0-29.9 166 (28.4)   85 (28.6) 81 (28.1)  51.2 (43.3-59.0) 
  ≥30 291 (49.7)   149 (50.2) 142 (49.3)  51.2 (45.3-57.1) 
Hypoxia (oxygen saturation ≤93%)           
  No 443 (75.7) 64  226 (76.1) 217 (75.3) <0.001 51.0 (46.3-55.8) 
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  Yes 78 (13.3)   58 (19.5) 20 (6.9)  74.4 (63.2-83.6) 
Pulse ≥90 beats per minute           
  No 295 (50.4) 33  150 (50.5) 145 (50.3) 0.20 50.9 (45.0-56.7) 
  Yes 257 (43.9)   145 (48.8) 112 (38.9)  56.4 (50.1-62.6) 
Systolic blood pressure, mm Hg           
    <90 63 (10.8) 37  43 (14.5) 20 (6.9) 0.04 68.3 (55.3-79.4) 
    90-140 274 (46.8)   145 (48.8) 129 (44.8)  52.9 (46.8-59.0) 
    ≥140 211 (36.1)   106 (35.7) 105 (36.5)  50.2 (43.3-57.2) 
Temperature, °F           
  ≤98.6 204 (34.9) 34  88 (29.6) 116 (40.3) 0.002 43.1 (36.2-50.2) 
  98.7-100.3 227 (38.8)   134 (45.1) 93 (32.3)  59.0 (52.3-65.5) 
  ≥100.4 120 (20.5)   70 (23.6) 50 (17.4)  58.3 (49.0-67.3)            
Laboratory findings at test date           
Alanine aminotransferase, U/L           
  Median (IQR) 28.0 (19.0-41.0) 41  30.0 (20.0-42.0) 26.0 (18.0-37.0) 0.01  
  ≤40 406 (69.4)   205 (69.0) 201 (69.8) 0.01 50.5 (45.5-55.5) 
  >40 138 (23.6)   87 (29.3) 51 (17.7)  63.0 (54.4-71.1) 
Albumin, g/dL           
  Median (IQR) 3.8 (3.5-4.2) 41  3.7 (3.3-4.0) 4.1 (3.7-4.3) <0.001  
  ≥3.5 415 (70.9)   191 (64.3) 224 (77.8) <0.001 46.0 (41.2-51.0) 
  <3.5 129 (22.1)   103 (34.7) 26 (9.0)  79.8 (71.9-86.4) 
Aspartate aminotransferase, U/L           
  Median (IQR) 29.0 (21.5-43.0) 37  35.5 (25.0-54.0) 25.0 (20.0-33.0) <0.001  
  ≤40 391 (66.8)   173 (58.2) 218 (75.7) <0.001 44.3 (39.3-49.3) 
  >40 157 (26.8)   121 (40.7) 36 (12.5)  77.1 (69.7-83.4) 
Creatinine, mg/dL           
  Median (IQR) 1.1 (1.0-1.5) 20  1.3 (1.0-1.8) 1.1 (0.9-1.3) <0.001  
  ≤1.5 435 (74.4)   200 (67.3) 235 (81.6) <0.001 46.0 (41.2-50.8) 
  >1.5 130 (22.2)   97 (32.7) 33 (11.5)  74.6 (66.2-81.8) 
eGFR, mL/min           
  Median (IQR) 71.5 (53.0-87.0) 17  63.0 (42.0-82.0) 75.0 (64.0-93.0) <0.001  
  ≥15 541 (92.5)   277 (93.3) 264 (91.7) 0.03 51.2 (46.9-55.5) 
  <15 27 (4.6)   20 (6.7) 7 (2.4)  74.1 (53.7-88.9) 
FIB-4           
  <1.45 139 (23.8) 69  36 (12.1) 103 (35.8) <0.001 25.9 (18.9-34.0) 
  1.45-3.25 263 (45.0)   153 (51.5) 110 (38.2)  58.2 (52.0-64.2) 
  >3.25 114 (19.5)   94 (31.6) 20 (6.9)  82.5 (74.2-88.9) 
Hemoglobin, g/dL           
  Median (IQR) 13.9 (12.6-14.9) 45  13.6 (12.0-14.7) 14.2 (13.2-15.1) <0.001  
  ≥10 523 (89.4)   273 (91.9) 250 (86.8) 0.02 52.2 (47.8-56.6) 
  <10 17 (2.9)   14 (4.7) 3 (1.0)  82.4 (56.6-96.2) 
Platelet count, K/µL           
  Median (IQR) 193 ( 154- 230) 48  175 ( 143- 216) 208 ( 173- 252) <0.001  
  ≥150 416 (71.1)   200 (67.3) 216 (75.0) <0.001 48.1 (43.2-53.0) 
  <150 121 (20.7)   88 (29.6) 33 (11.5)  72.7 (63.9-80.4) 
White blood cell count, K/µL           
  Median (IQR) 5.9 (4.7-7.5) 32  5.9 (4.6-7.7) 5.9 (4.7-7.3) 0.54  
  <4 72 (12.3)   42 (14.1) 30 (10.4) 0.005 58.3 (46.1-69.9) 
  4-9.9 432 (73.8)   217 (73.1) 215 (74.7)  50.2 (45.4-55.1) 
  ≥10 49 (8.4)   36 (12.1) 13 (4.5)  73.5 (58.9-85.1) 
  Lymphocyte count, K/µL           
    Median (IQR) 1.1 (0.8-1.6) 92  0.9 (0.6-1.3) 1.4 (1.0-1.9) <0.001  
      ≥0.8 363 (62.1)   179 (60.3) 184 (63.9) <0.001 49.3 (44.1-54.6) 
      <0.8 130 (22.2)   105 (35.4) 25 (8.7)  80.8 (72.9-87.2) 
VACS Index scoreb, median (IQR) 72.4 (63.6-82.5) 51   78.7 (71.1-87.3) 66.2 (60.0-73.2) <0.001   
Abbreviations: Covid-19, coronavirus disease 2019; IQR, interquartile range; eGFR, estimated glomerular filtration rate, FIB-4, fibrosis 4 score; VACS, Veterans Aging Cohort 
Study 
aP-values calculated on non-missing data 
bThe VACS Index score is a validated measure of physiologic injury and combining age, aspartate and alanine transaminase, albumin, creatinine, hemoglobin, platelets, white 
blood cell count, hepatitis C status, and body mass index  
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Table 3b. Associations with intensive care among Covid-19 cases aged 54-75 years in the Veterans Health Administration as of March 30, 2020 
     Intensive care 
  No. cases (%) missing   Yes (%) No (%) p-valuea 
% admitted 
(95% CI) 
n 585 (100)   122 (100.0) 463 (100.0)  20.9 (17.6-24.4)            
Demographics           
Age, years           
  Median (IQR) 66.1 (60.4-71.0) 0  69.9 (64.4-71.7) 64.7 (59.8-70.8) <0.001  
  54-59 135 (23.1)   11 (9.0) 124 (26.8) <0.001 8.2 (4.1-14.1) 
  60-64 135 (23.1)   24 (19.7) 111 (24.0)  17.8 (11.7-25.3) 
  65-69 120 (20.5)   28 (23.0) 92 (19.9)  23.3 (16.1-31.9) 
  70-75 195 (33.3)   59 (48.4) 136 (29.4)  30.3 (23.9-37.2) 
Sex           
  Female 27 (4.6) 0  3 (2.5) 24 (5.2) 0.33 11.1 (2.4-29.2) 
  Male 558 (95.4)   119 (97.5) 439 (94.8)  21.3 (18.0-25.0) 
Race/ethnicity           
  White 161 (27.5) 0  37 (30.3) 124 (26.8) 0.89 23.0 (16.7-30.3) 
  Black 350 (59.8)   71 (58.2) 279 (60.3)  20.3 (16.2-24.9) 
  Latinx 48 (8.2)   9 (7.4) 39 (8.4)  18.8 (9.0-32.6) 
  Other/unknown 26 (4.4)   5 (4.1) 21 (4.5)  19.2 (6.6-39.4) 
Residence type           
  Rural 56 (9.6) 0  9 (7.4) 47 (10.2) 0.49 16.1 (7.6-28.3) 
  Urban 529 (90.4)   113 (92.6) 416 (89.8)  21.4 (17.9-25.1)            
Baseline comorbidity           
Asthma           
  No 540 (92.3) 0  111 (91.0) 429 (92.7) 0.57 20.6 (17.2-24.2) 
  Yes 45 (7.7)   11 (9.0) 34 (7.3)  24.4 (12.9-39.5) 
Cancer           
  No 502 (85.8) 0  104 (85.2) 398 (86.0) 0.88 20.7 (17.3-24.5) 
  Yes 83 (14.2)   18 (14.8) 65 (14.0)  21.7 (13.4-32.1) 
Chronic kidney disease           
  No 474 (81.0) 0  90 (73.8) 384 (82.9) 0.03 19.0 (15.6-22.8) 
  Yes 111 (19.0)   32 (26.2) 79 (17.1)  28.8 (20.6-38.2) 
Chronic obstructive pulmonary disease           
  No 495 (84.6) 0  94 (77.0) 401 (86.6) 0.02 19.0 (15.6-22.7) 
  Yes 90 (15.4)   28 (23.0) 62 (13.4)  31.1 (21.8-41.7) 
Diabetes mellitus           
  No 325 (55.6) 0  49 (40.2) 276 (59.6) <0.001 15.1 (11.4-19.4) 
  Yes 260 (44.4)   73 (59.8) 187 (40.4)  28.1 (22.7-34.0) 
Hypertension           
  No 162 (27.7) 0  17 (13.9) 145 (31.3) <0.001 10.5 (6.2-16.3) 
  Yes 423 (72.3)   105 (86.1) 318 (68.7)  24.8 (20.8-29.2) 
Liver disease           
  No 525 (89.7) 0  107 (87.7) 418 (90.3) 0.40 20.4 (17.0-24.1) 
  Yes 60 (10.3)   15 (12.3) 45 (9.7)  25.0 (14.7-37.9) 
Vascular disease           
  No 422 (72.1) 0  74 (60.7) 348 (75.2) 0.002 17.5 (14.0-21.5) 
  Yes 163 (27.9)   48 (39.3) 115 (24.8)  29.5 (22.6-37.1)            
Substance use           
Alcohol use disorder           
  No 537 (91.8) 0  115 (94.3) 422 (91.1) 0.35 21.4 (18.0-25.1) 
  Yes 48 (8.2)   7 (5.7) 41 (8.9)  14.6 (6.1-27.8) 
Smoking           
  Never 216 (36.9) 31  43 (35.2) 173 (37.4) 0.60 19.9 (14.8-25.9) 
  Former 179 (30.6)   36 (29.5) 143 (30.9)  20.1 (14.5-26.7) 
  Current 159 (27.2)   38 (23.9) 121 (26.1)  23.9 (17.5-31.3)            
Medication history in year prior to test date           
Any angiotensin converting enzyme inhibitor or 
angiotensin II receptor blocker 
          
  No 330 (56.4) 0  53 (43.4) 277 (59.8) 0.001 16.1 (12.3-20.5) 
  Yes 255 (43.6)   69 (56.6) 186 (40.2)  27.1 (21.7-33.0) 
Angiotensin converting enzyme inhibitor           
    No 416 (71.1) 0  72 (59.0) 344 (74.3) 0.002 17.3 (13.8-21.3) 
    Yes 169 (28.9)   50 (41.0) 119 (25.7)  29.6 (22.8-37.1) 
Angiotensin II receptor blocker           
    No 491 (83.9) 0  99 (81.1) 392 (84.7) 0.34 20.2 (16.7-24.0) 
    Yes 94 (16.1)   23 (18.9) 71 (15.3)  24.5 (16.2-34.4) 
Chemotherapy or immunsuppresive drug           
  No 556 (95.0) 0  115 (94.3) 441 (95.2) 0.64 20.7 (17.4-24.3) 
  Yes 29 (5.0)   7 (5.7) 22 (4.8)  24.1 (10.3-43.5) 
Nonsteroidal anti-inflammatory drug, (-365, -14 days)           
    No 392 (67.0) 0  90 (73.8) 302 (65.2) 0.08 23.0 (18.9-27.5) 
    Yes 193 (33.0)   32 (26.2) 161 (34.8)  16.6 (11.6-22.6)            
Vital signs at test date            
Body mass index, kg/m2           
  <25.0 73 (12.5) 55  19 (15.6) 54 (11.7) 0.18 26.0 (16.5-37.6) 
  25.0-29.9 166 (28.4)   28 (23.0) 138 (29.8)  16.9 (11.5-23.5) 
  ≥30 291 (49.7)   67 (23.0) 224 (48.4)  23.0 (18.3-28.3) 
Hypoxia (oxygen saturation ≤93%)           
  No 443 (75.7) 64  87 (71.3) 356 (76.9) <0.001 19.6 (16.0-23.7) 
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  Yes 78 (13.3)   30 (24.6) 48 (10.4)  38.5 (27.7-50.2) 
Pulse ≥90 beats per minute           
  No 295 (50.4) 33  53 (43.4) 242 (52.3) 0.02 18.0 (13.8-22.8) 
  Yes 257 (43.9)   68 (55.7) 189 (40.8)  26.5 (21.2-32.3) 
Systolic blood pressure, mm Hg           
    <90 63 (10.8) 37  17 (13.9) 46 (9.9) 0.57 27.0 (16.6-39.7) 
    90-140 274 (46.8)   60 (49.2) 214 (46.2)  21.9 (17.2-27.3) 
    ≥140 211 (36.1)   44 (36.1) 167 (36.1)  20.9 (15.6-27.0) 
Temperature, °F           
  ≤98.6 204 (34.9) 34  28 (23.0) 176 (38.0) 0.002 13.7 (9.3-19.2) 
  98.7-100.3 227 (38.8)   56 (45.9) 171 (36.9)  24.7 (19.2-30.8) 
  ≥100.4 120 (20.5)   34 (27.9) 86 (18.6)  28.3 (20.5-37.3)            
Laboratory findings at test date           
Alanine aminotransferase, U/L           
  Median (IQR) 28.0 (19.0-41.0) 41  32.0 (21.0-47.0) 27.0 (19.0-38.0) 0.02  
  ≤40 406 (69.4)   78 (63.9) 328 (70.8) 0.004 19.2 (15.5-23.4) 
  >40 138 (23.6)   43 (35.2) 95 (20.5)  31.2 (23.6-39.6) 
Albumin, g/dL           
  Median (IQR) 3.8 (3.5-4.2) 41  3.6 (3.2-3.9) 3.9 (3.6-4.2) <0.001  
  ≥3.5 415 (70.9)   68 (55.7) 347 (74.9) <0.001 16.4 (13.0-20.3) 
  <3.5 129 (22.1)   54 (44.3) 75 (16.2)  41.9 (33.2-50.9) 
Aspartate aminotransferase, U/L           
  Median (IQR) 29.0 (21.5-43.0) 37  42.0 (27.0-68.0) 27.0 (21.0-39.0) <0.001  
  ≤40 391 (66.8)   59 (48.4) 332 (71.7) <0.001 15.1 (11.7-19.0) 
  >40 157 (26.8)   63 (51.6) 94 (20.3)  40.1 (32.4-48.2) 
Creatinine, mg/dL           
  Median (IQR) 1.1 (1.0-1.5) 20  1.4 (1.1-2.0) 1.1 (0.9-1.4) <0.001  
  ≤1.5 435 (74.4)   72 (59.0) 363 (78.4) <0.001 16.6 (13.2-20.4) 
  >1.5 130 (22.2)   50 (41.0) 80 (17.3)  38.5 (30.1-47.4) 
eGFR, mL/min           
  Median (IQR) 71.5 (53.0-87.0) 17  55.5 (37.0-76.0) 74.0 (58.0-90.0) <0.001  
  ≥15 541 (92.5)   110 (90.2) 431 (93.1) 0.006 20.3 (17.0-24.0) 
  <15 27 (4.6)   12 (9.8) 15 (3.2)  44.4 (25.5-64.7) 
FIB-4           
  <1.45 139 (23.8) 69  6 (4.9) 133 (28.7) <0.001 4.3 (1.6-9.2) 
  1.45-3.25 263 (45.0)   66 (54.1) 197 (42.5)  25.1 (20.0-30.8) 
  >3.25 114 (19.5)   44 (36.1) 70 (15.1)  38.6 (29.6-48.2) 
Hemoglobin, g/dL           
  Median (IQR) 13.9 (12.6-14.9) 45  13.6 (11.9-14.7) 14.0 (12.8-15.0) 0.02  
  ≥10 523 (89.4)   109 (89.3) 414 (89.4) 0.02 20.8 (17.4-24.6) 
  <10 17 (2.9)   8 (6.6) 9 (1.9)  47.1 (23.0-72.2) 
Platelet count, K/µL           
  Median (IQR) 193 ( 154- 230) 48  175 ( 144- 228) 195 ( 157- 231) 0.05  
  ≥150 416 (71.1)   82 (19.7) 334 (72.1) 0.03 19.7 (16.0-23.9) 
  <150 121 (20.7)   35 (28.9) 86 (18.6)  28.9 (21.1-37.9) 
White blood cell count, K/µL           
  Median (IQR) 5.9 (4.7-7.5) 32  6.2 (5.2-8.9) 5.7 (4.6-7.2) <0.001  
  <4 72 (12.3)   12 (16.7) 60 (13.0) 0.002 16.7 (8.9-27.3) 
  4-9.9 432 (73.8)   89 (20.6) 343 (74.1)  20.6 (16.9-24.7) 
  ≥10 49 (8.4)   21 (42.9) 28 (6.0)  42.9 (28.8-57.8) 
  Lymphocyte count, K/µL           
    Median (IQR) 1.1 (0.8-1.6) 92  0.8 (0.6-1.1) 1.2 (0.8-1.8) <0.001  
      ≥0.8 363 (62.1)   71 (19.6) 292 (63.1) <0.001 19.6 (15.6-24.0) 
      <0.8 130 (22.2)   48 (36.9) 82 (17.7)  36.9 (28.6-45.8) 
VACS Index scoreb, median (IQR) 72.4 (63.6-82.5) 51   82.0 (74.0-91.1) 69.4 (61.1-79.1) <0.001   
Abbreviations: Covid-19, coronavirus disease 2019; IQR, interquartile range; eGFR, estimated glomerular filtration rate, FIB-4, fibrosis 4 score; VACS, Veterans Aging Cohort 
Study 
aP-values calculated on non-missing data 
bThe VACS Index score is a validated measure of physiologic injury and combining age, aspartate and alanine transaminase, albumin, creatinine, hemoglobin, platelets, white 
blood cell count, hepatitis C status, and body mass index  
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Table 4. Crude and adjusted associations with hospitalization and intensive care among Covid-19 cases as of March 30, 2020 
 Hospitalization (n=297/585)  Intensive care (n=122/585) 
  Univariable OR (95% CI) 
Multivariable OR 
(95% CI) 
Multivariable OR 
(95% CI)   
Univariable OR 
(95% CI) 
Multivariable OR 
(95% CI) 
Multivariable OR 
(95% CI) 
Model details        
C-statistic - 0.859 0.834  - 0.876 0.835         
Demographics        
Age, per 5-year increase 1.26 (1.10-1.44) 0.87 (0.71-1.05) 0.64 (0.51-0.80)  1.55 (1.30-1.86) 1.31 (1.03-1.66) 0.98 (0.76-1.26) 
Race/ethnicity, black vs. other 1.30 (0.94-1.82) 0.96 (0.61-1.53) 1.14 (0.74-1.74)  0.92 (0.61-1.38) 0.94 (0.55-1.63) 0.98 (0.60-1.61)         
Baseline comorbidity        
Chronic kidney disease, yes vs. no 2.36 (1.53-3.66) 0.80 (0.41-1.56) 0.84 (0.47-1.49)  1.73 (1.08-2.77) 0.50 (0.24-1.06) 0.65 (0.35-1.21) 
Chronic obstructive pulmonary disease, yes vs. no 2.31 (1.43-3.72) 1.77 (0.92-3.41) 1.15 (0.62-2.12)  1.93 (1.17-3.18) 1.81 (0.92-3.58) 1.47 (0.79-2.73) 
Diabetes mellitus, yes vs. no  1.96 (1.41-2.73) 1.59 (1.00-2.53) 1.36 (0.89-2.09)  2.20 (1.46-3.30) 1.69 (0.96-2.98) 1.41 (0.85-2.35) 
Hypertension, yes vs.no  2.25 (1.55-3.26) 1.39 (0.78-2.46) 1.50 (0.88-2.54)  2.81 (1.63-4.88) 1.51 (0.70-3.28) 1.89 (0.93-3.87) 
Vascular disease, yes vs. no 2.92 (1.99-4.29) 1.58 (0.93-2.69) 1.58 (0.96-2.60)  1.96 (1.29-2.99) 0.73 (0.40-1.33) 0.77 (0.44-1.34)         
Medication history in year prior to test date        
Angiotensin converting enzyme inhibitor or 
angiotensin II receptor blocker, yes vs. no 1.63 (1.17-2.27) 1.15 (0.71-1.87) 1.24 (0.79-1.95) 
 1.94 (1.30-2.90) 1.66 (0.94-2.93) 1.69 (1.01-2.84) 
Nonsteroidal anti-inflammatory drug, yes vs. no 0.78 (0.55-1.10) 1.18 (0.74-1.89) 1.09 (0.71-1.67)  0.67 (0.43-1.04) 1.16 (0.65-2.06) 0.98 (0.57-1.67)         
Vital signs        
Systolic blood pressure, per 5 mm Hg decrease 1.10 (1.03-1.17) 1.08 (1.00-1.18) 1.09 (1.00-1.17)  1.05 (0.98-1.13) 1.00 (0.92-1.10) 1.00 (0.91-1.09) 
Oxygen saturation, per 1% decrease 1.14 (1.06-1.23) 1.04 (0.95-1.14) 1.12 (1.02-1.22)  1.16 (1.09-1.24) 1.05 (0.97-1.14) 1.13 (1.05-1.21) 
Pulse, per 5-beats per minute increase 0.97 (0.95-0.99) 0.97 (0.95-099) 0.97 (0.95-0.99)  0.99 (0.97-1.00) 1.00 (0.97-1.02) 0.99 (0.97-1.01) 
Temperature, per 1°F increase 1.20 (1.07-1.36) 1.15 (0.98-1.34) 1.24 (1.08-1.44)  1.28 (1.12-1.47) 1.32 (1.10-1.58) 1.37 (1.16-1.61)         
Laboratory findings        
Albumin, per 1 g/dL decrease 10.43 (5.70-19.08) 3.75 (1.91-7.35) -  6.17 (3.62-10.52) 3.34 (1.70-6.54) - 
eGFR, per 10 mL/min decrease 1.29 (1.19-1.40) 1.18 (1.05-1.32) -  1.31 (1.21-1.43) 1.29 (1.15-1.46) - 
FIB-4        
  <1.45 ref ref -  ref ref - 
  1.45-3.25 3.92 (2.53-6.08) 2.96 (1.69-5.17) -  6.31 (2.74-14.50) 4.59 (1.72-12.22) - 
  >3.25 12.37 (6.73-22.72) 8.73 (4.11-18.56) -  12.43 (5.24-29.50) 8.40 (2.90-24.28) - 
Hemoglobin, per 1 g/dL decrease 1.55 (1.32-1.83) 1.16 (0.93-1.43) -  1.33 (1.14, 1.54) 1.00 (0.81-1.23) - 
White blood cell count, per 1 K/µL increase 1.05 (0.96-1.15) 1.24 (1.08-1.43) -  1.22 (1.10-1.36) 1.49 (1.27-1.73) - 
Lymphocyte count, per 1 K/µL decrease 2.68 (2.00-3.60) 2.38 (1.68-3.39) -  2.76 (1.87-4.09) 2.65 (1.68-4.18) - 
VACS Index scorea, per 5-point increase 1.48 (1.36-1.61) - 1.62 (1.43-1.84)   1.45 (1.33-1.58) - 1.47 (1.31-1.65) 
Abbreviations: Covid-19, coronavirus disease 2019; OR, odds ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate, FIB-4, fibrosis 4 score; VACS, Veterans Aging Cohort 
Study 
aThe VACS Index score is a validated measure of physiologic injury combining age, aspartate and alanine transaminase, albumin, creatinine, hemoglobin, platelets, white blood cell count, 
hepatitis C status, and body mass index  
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eMethods 
Functional forms of vital signs and laboratory results  
After assessing the distribution and crude shapes of associations, each vital sign and laboratory measure used in 
multivariable analyses were processed for analysis using the following steps. Body mass index (BMI) was 
treated as a linear variable and assessed per 5 kg/m2 increase, which broadly aligns with widely used categories. 
Pulse rate was treated as a linear variable and assessed per 5-beats per minute increase. Temperature was treated 
as a linear variable and assessed per 1°F increase.  
 
We transformed systolic blood pressure, oxygen saturation, and all labs used in multivariable analyses to benefit 
clinical interpretation. Systolic blood pressure values above 140 mm Hg were truncated, and we assessed linear 
associations per 5 mm Hg decrease. Oxygen saturation values above 98% were truncated, and we assessed 
linear associations per 1% decrease. Albumin values above 4 g/dL were truncated, and we assessed linear 
associations per 1 g/dL decrease. eGFR values above 90 mL/min were truncated, and we assessed linear 
associations per 10 mL/min decrease. Hemoglobin values above 14 g/dL were truncated, and we assessed linear 
associations per 1 g/dL decrease. White blood cell counts below 4 K/µL and above 10 K/µL were truncated, and 
we assessed linear associations per 1 K/µL increase. Lymphocyte counts above 5 K/µL were truncated, and we 
assessed linear associations per 1 K/µL decrease. VACS Index score was treated as a linear variable and 
assessed per 5-point increase. 
 
Calculating VACS Index 
Full details on constructing the VACS Index in a Veteran population have been published previously.1 In brief, 
the VACS Index is a summary measure combining age, aspartate and alanine transaminase, albumin, creatinine, 
hemoglobin, platelets, white blood cell count, hepatitis C status, and body mass index. (Among people with 
HIV, we also consider HIV-1 viral load and CD4 count. These components were not used in this analysis.) 
Composite markers of liver and renal injury were calculated. FIB-4 is a validated indicator of liver fibrosis.2 
Estimated glomerular filtration rate (eGFR) is a validated indicator of impaired renal function.3 Hepatitis C 
status was based on presence of ICD-10-CM codes (eTable 1).  
 
Because clinicians tend to order laboratory tests that they are concerned to be abnormal, we assumed laboratory 
values as normal if it was the only missing value for calculating the VACS Index. We used continuous 
functional forms for each variable including quadratic, cubic, and natural log terms to account for U-shaped 
associations. Splines were used for eGFR. Using regression coefficients from the original validation work, we 
applied regression equations to each patient using their lab values and the model coefficients to create linear 
predictors for each patient, which were then scaled to create scores of approximately 0 to 100. 
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eTable 1. Conditions based on International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) 
Diagnosis Codes 
      ICD-10-CM codes 
Comorbid conditions 
 
 
Asthma 
 
J45.X  
Cancer 
  
  
Cancer C00.X-C43.X, C45.X-C76.X, C80.X-C96.X, C7A.X   
Metastatic cancer C77.X-C79.X   
Chronic obstructive pulmonary disease J41.X, J42.X, J43.X, J44.X  
Chronic kidney disease I12.0X, I13.1X, N03.2X-N03.7X, N18.X, N19.X, N05.2X-N05.7X, N25.0X, 
Z49.0X - Z49.2X, Z94.0X, Z99.2X  
Diabetes mellitus E08.X, E10.X, E11.X, E13.X  
Hypertension I10.X-I13.X, I15.X, I16.X  
Liver disease 
 
  
Hepatitis B virus B16.X, B18.0X, B18.1X, B19.1X, Z22.51    
Hepatitis C virus B17.10, B17.11, B18.2, B19.20, B19.21, Z22.52   
Hepatic decompensation I85.01, K65.2, K70.31, K72.1X, K72.9X, K76.7, R18.8    
Other mild liver disease B18.8X, B18.9X, K70.0X-K70.2X, K70.30, K70.9X, K71.3X-K71.5X, K71.7X, 
K73.X, K74.X, K76.0X, K76.2X-K76.4X, K76.8X, K76.9X, Z94.4   
Other severe liver disease K76.6, I85.00, I85.9X, I86.4, I98.2X, K70.4X, K71.1X, K76.5X   
Vascular disease 
 
  
Acute myocardial infarction I21.X (not including I21.AX), I22.X   
Cardiomyopathy I42.X, I43.X   
Coronary heart disease I20.X, I24.X, I25.10, I25.110, I25.2, I25.3, I25.41, I25.42, I25.5, I25.700, 
I25.710, I25.720, I25.730, I25.750, I25.760, I25.790, I25.8X, I25.9   
Heart failure I09.9, I11.0, I25.5, I13.0, I13.2, I50.X, P29.0   
Cerebrovascular accident I60.X-I69.X, G45.X, G46.X, H34.0   
Peripheral vascular disease I70.X, I71.X, I73.1-I73.9, I77.1, I79.0, I79.2, K55.1X, K55.8X, K55.9X, 
Z95.8X, Z95.9 
Substance use 
  
  Alcohol use disorder F10.1X, F10.2X 
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eTable 2. Complete-case analysis estimating crude and adjusted associations with testing positive for Covid-19 as of 
March 30, 2020 
 Positive Covid-19 test (n=585/3789) 
  Univariable       OR (95% CI) 
Multivariable     
OR (95% CI) 
Conditional      
ORa (95% CI) 
Model details    
Number complete cases - 2458 1366 
C-statistic - 0.820 n/a     
Demographics    
Age, per 5-year increase 1.04 (0.97-1.12) 1.04 (0.93-1.15) 1.04 (0.91-1.19) 
Sex, male vs. female 2.49 (1.67-3.73) 3.51 (2.06-5.95) 4.59 (2.37-8.89) 
Race/ethnicity, black vs. other 4.66 (3.88-5.60) 5.68 (4.43-7.28) 2.71 (1.91-3.86) 
Residence type, urban vs. rural 2.46 (1.84-3.28) 1.65 (1.12-2.44) 1.00 (0.56-1.78)     
Baseline comorbidity    
Chronic kidney disease, yes vs. no 1.43 (1.14-1.80) 1.02 (0.74-1.40) 1.01 (0.68-1.50) 
Chronic obstructive pulmonary disease, yes vs. no 0.46 (0.37-0.59) 0.69 (0.51-0.93) 0.81 (0.55-1.19) 
Diabetes mellitus, yes vs. no  1.39 (1.16-1.66) 0.96 (0.74-1.25) 0.78 (0.56-1.08) 
Hypertension, yes vs.no  1.49 (1.23-1.81) 1.27 (0.93-1.75) 1.41 (0.95-2.11)     
Substance use    
Alcohol use disorder, yes vs. no 0.51 (0.37-0.69) 0.52 (0.35-0.78) 0.48 (0.29-0.78) 
Current smoking, yes vs. no 0.43 (0.35-0.52) 0.41 (0.31-0.53) 0.41 (0.30-0.58)     
Medication history in year prior to test date    
Angiotensin converting enzyme inhibitor or angiotensin 
II receptor blocker, yes vs. no 1.17 (0.98-1.39) 1.05 (0.81-1.37) 0.98 (0.70-1.36) 
Nonsteroidal anti-inflammatory drug, yes vs. no 1.15 (0.95-1.39) 1.31 (1.01-1.69) 1.18 (0.85-1.64)     
Vital signs    
Systolic blood pressure, <140 vs. ≥140 mm Hg 1.22 (1.01-1.47) 1.46 (1.14-1.86) 1.47 (1.08-2.00) 
Body mass index, per 5-unit increase 1.15 (1.08-1.23) 1.09 (0.99-1.19) 1.12 (1.00-1.25) 
Oxygen saturation, ≤93% vs >93% 0.84 (0.64-1.09) 0.98 (0.71-1.37) 0.96 (0.60-1.54) 
Pulse, per 5-beats per minute increase 1.05 (1.02-1.08) 1.03 (1.00-1.07) 1.05 (1.00-1.10) 
Temperature, per 1°F increase 1.73 (1.61-1.85) 1.62 (1.48-1.78) 1.55 (1.38-1.74) 
Abbreviations: Covid-19, coronavirus disease 2019; OR, odds ratio; CI, confidence interval 
aModeling stations with five or more Covid-19 cases and conditioning on station 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
eTable 3. Complete-case analysis estimating crude and adjusted associations with hospitalization and intensive care among Covid-19 cases as of March 30, 2020 
 Hospitalization (n=297/585)  Intensive care (n=122/585) 
  Univariable                OR (95% CI) 
Multivariable             
OR (95% CI) 
Multivariable             
OR (95% CI)   
Univariable              
OR (95% CI) 
Multivariable            
OR (95% CI) 
Multivariable            
OR (95% CI) 
Model details        
Number complete cases - 404 484  - 404 484 
C-statistic - 0.822 0.812  - 0.864 0.828         
Demographics        
Age, per 5-year increase 1.26 (1.10-1.44) 0.97 (0.78-1.21) 0.67 (0.53-0.85)  1.55 (1.30-1.86) 1.33 (1.01-1.74) 1.03 (0.79-1.35) 
Race/ethnicity, black vs. other 1.30 (0.94-1.82) 1.04 (0.60-1.78) 1.08 (0.68-1.71)  0.92 (0.61-1.38) 0.94 (0.50-1.75) 1.01 (0.59-1.71)         
Baseline comorbidity        
Chronic kidney disease, yes vs. no 2.36 (1.53-3.66) 0.97 (0.45-2.09) 0.93 (0.50-1.74)  1.73 (1.08-2.77) 0.58 (0.25-1.33) 0.80 (0.42-1.52) 
Chronic obstructive pulmonary disease, yes vs. no 2.31 (1.43-3.71) 1.34 (0.64-2.85) 0.98 (0.51-1.87)  1.93 (1.17-3.18) 1.21 (0.56-2.58) 1.21 (0.63-2.35) 
Diabetes mellitus, yes vs. no  1.96 (1.41-2.73) 1.62 (0.95-2.77) 1.36 (0.86-2.15)  2.20 (1.46-3.30) 1.79 (0.94-3.39) 1.45 (0.85-2.48) 
Hypertension, yes vs.no  2.25 (1.55-3.26) 1.23 (0.64-2.37) 1.62 (0.92-2.85)  2.82 (1.63-4.88) 1.65 (0.68-4.01) 1.89 (0.88-4.05) 
Vascular disease, yes vs. no 2.92 (1.99-4.29) 1.36 (0.75-2.46) 1.51 (0.88-2.57)  1.96 (1.29-2.99) 0.75 (0.39-1.43) 0.80 (0.45-1.42)         
Medication history in year prior to test date        
Angiotensin converting enzyme inhibitor or angiotensin 
II receptor blocker, yes vs. no 1.63 (1.17-2.27) 1.15 (0.66-1.99) 1.15 (0.71-1.86) 
 1.94 (1.30-2.90) 1.44 (0.78-2.68) 1.57 (0.92-2.70) 
Nonsteroidal anti-inflammatory drug, yes vs. no 0.78 (0.55-1.10) 1.06 (0.62-1.80) 1.01 (0.64-1.59)  0.67 (0.43-1.04) 0.97 (0.50-1.85) 0.85 (0.48-1.50)         
Vital signs        
Systolic blood pressure, per 5 mm Hg decrease 1.11 (1.04-1.18) 1.12 (1.01-1.23) 1.09 (1.00-1.18)  1.05 (0.98-1.13) 1.01 (0.91-1.11) 1.00 (0.92-1.10) 
Oxygen saturation, per 1% decrease 1.15 (1.07-1.24) 1.07 (0.95-1.19) 1.14 (1.03-1.25)  1.16 (1.09-1.24) 1.05 (0.96-1.15) 1.11 (1.03-1.19) 
Pulse, per 5-beats per minute increase 1.06 (1.01-1.12) 1.03 (0.95-1.11) 1.02 (0.95-1.10)  1.13 (1.06-1.20) 1.13 (1.04-1.23) 1.12 (1.03-1.21) 
Temperature, per 1°F increase 1.20 (1.07-1.36) 1.14 (0.96-1.36) 1.24 (1.06-1.45)  1.28 (1.12-1.47) 1.33 (1.08-1.63) 1.36 (1.14-1.61)         
Laboratory findings        
Albumin, per 1 g/dL decrease 10.92 (5.88-20.25) 2.70 (1.27-5.73) -  5.91 (3.45-10.12) 3.99 (1.81-8.80) - 
eGFR, per 10 mL/min decrease 1.29 (1.19-1.39) 1.15 (1.00-1.31) -  1.31 (1.20-1.42) 1.29 (1.12-1.48) - 
FIB-4        
  <1.45 ref ref -  ref ref - 
  1.45-3.25 3.98 (2.53-6.25) 2.11 (1.11-4.02) -  7.42 (3.13-17.62) 4.59 (1.39-15.13) - 
  >3.25 13.45 (7.28-24.84) 5.52 (2.39-12.75) -  13.93 (5.66-34.29) 6.88 (1.94-24.39) - 
Hemoglobin, per 1 g/L decrease 1.51 (1.29-1.78) 1.09 (0.85-1.40) -  1.28 (1.10-1.48) 0.96 (0.75-1.21) - 
White blood cell count, per 1 K/µL increase 1.06 (0.97-1.16) 1.23 (1.05-1.44) -  1.23 (1.11-1.37) 1.41 (1.18-1.68) - 
Lymphocyte count, per 1 K/µL decrease 2.62 (1.95-3.52) 2.30 (1.52-3.46) -  2.52 (1.70-3.74) 2.42 (1.44-4.07) - 
VACS Index scorea, per 5-point increase 1.47 (1.35-1.60) - 1.55 (1.36-1.77)   1.45 (1.33-1.58) - 1.44 (1.27-1.64) 
Abbreviations: Covid-19, coronavirus disease 2019; OR, odds ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate, FIB-4, fibrosis 4 score; VACS, Veterans Aging Cohort Study 
aThe VACS Index score is a validated measure of physiologic injury combining age, aspartate and alanine transaminase, albumin, creatinine, hemoglobin, platelets, white blood cell count, hepatitis C status, and 
body mass index  
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